Tuesday, August 18, 2026
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO NA Magazine > News > Moderna sues Pfizer/BioNTech over Covid vaccine technology

Moderna sues Pfizer/BioNTech over Covid vaccine technology

in News
Moderna sues Pfizer/BioNTech over Covid vaccine technology
Share on LinkedinShare on WhatsApp

Moderna is suing Pfizer and BioNTech for patent infringement in the development of the first U.S. Covid-19 vaccine approved, the company announced Friday.

The Cambridge, Massachusetts firm claims partners Pfizer and BioNTech, without permission, copied mRNA technology that Moderna had patented between 2010 and 2016, well before Covid-19 emerged late 2019.

“We are filing these lawsuits to protect the innovative mRNA technology platform that we pioneered, invested billions of dollars in creating, and patented during the decade preceding the Covid-19 pandemic,” Moderna CEO Stephane Bancel said in the statement.

Moderna had been an innovator in the messenger RNA (mRNA) vaccine technology, which shortens approval processes to months, instead of the years it took to be completed.

The lawsuit was filed in U.S. District Court in Massachusetts and the Regional Court of Dusseldorf in Germany.

The U.S. Food and Drug Administration granted emergency use authorization for the vaccine to both Pfizer/BioNTech and Moderna in consecutive weeks in December 2020.

New York based Pfizer and Mainz, Germany based BioNTech are already facing multiple lawsuits from other companies who say the partnership’s vaccine infringes on their patents.

Moderna has also been sued for patent infringement in the U.S. and has an ongoing dispute with the U.S. National Institutes of Health over rights to mRNA technology.

Tags: BioNTechCOVID vaccineFDAModernaPfizer

Related Posts

Goldman Sachs reports 22% jump in profits
News

Goldman Sachs to acquire LCN Capital Partners for $410 million

US stock exchanges end week up
News

30-year Treasury yield reaches 19-year high

Home Depot CFO delivers strategic update as company offers cautious forecast
News

Home Depot reaffirms guidance amid ‘broad based demand’

L3Harris Technologies appoints Sam Mehta as President and CEO
News

L3Harris Technologies appoints Sam Mehta as President and CEO

AMD and Meta announce expanded strategic partnership 
News

Meta set to appear in major social media addiction trial

New 10% tariff for nations supporting ‘anti-American’ BRICS policies
News

Oil prices rise as U.S.-Iran ceasefire expires

Musk pledges new Tesla technology following $1 trillion pay package approval
News

Musk reveals 48.4% ownership stake in SpaceX through regulatory filing

Sources say Reddit’s IPO is significantly oversubscribed
News

Reddit stock surges 12% after S&P 500 inclusion

OpenAI announces partnerships with Accenture, BCG, Capgemini, and McKinsey
News

OpenAI appoints Dali Rajic as Chief Revenue Officer

Blackstone to acquire Skroutz in $74 million deal
News

Cerebras stock falls 15% despite raising outlook

No Result
View All Result

Recent Posts

  • Employees Want Their Bosses to Respond to Feedback — But Not Too Quickly
  • China leads wave of clean power wastage as grids globally hit limits
  • Goldman Sachs to acquire LCN Capital Partners for $410 million
  • 30-year Treasury yield reaches 19-year high
  • Home Depot reaffirms guidance amid ‘broad based demand’

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

Avenida Chapultepec 480,
Floor 11
Mexico City
06700
MEXICO

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

Avenida Chapultepec 480,
Floor 11
Mexico City
06700
MEXICO

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.